Core Viewpoint - The company has signed a technology transfer agreement for a new traditional Chinese medicine, which is expected to enhance its R&D capabilities and competitiveness in the market [1] Group 1: Agreement Details - On August 4, 2025, the company signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute [1] - The company acquired the clinical trial approval, patent rights, and related technical materials for the Class 1 new drug "Chaiqin Ning Shen Granules" for a total of 22 million RMB [1] - This transaction does not constitute a related party transaction and does not require approval from the board of directors or shareholders [1] Group 2: Strategic Implications - The acquisition is expected to facilitate the rapid expansion of the company's pipeline for innovative traditional Chinese medicine [1] - It aims to accelerate the development of new products, thereby enhancing the company's core competitiveness and sustainable development capabilities [1] - The transaction aligns with the company's development strategy and benefits all shareholders [1] Group 3: Financial Impact - The transaction is not expected to have a significant impact on the company's operating performance in the short term [1]

Core Viewpoint - The company, Yabao Pharmaceutical, has signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute for a new traditional Chinese medicine project, acquiring the clinical trial approval, patent rights, and related technical materials for the new drug "Chaiqin Ning Shen Granules" for 22 million yuan [1] Group 1 - The agreement was signed on August 4, indicating a strategic move by the company to expand its product portfolio in the traditional Chinese medicine sector [1] - The acquisition includes the clinical trial approval, which is crucial for the drug's development and commercialization [1] - The financial commitment of 22 million yuan reflects the company's investment in innovative drug development [1]

Group 1 - The company, Yabao Pharmaceutical (600351.SH), signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute on August 4, 2025 [1] - The agreement involves the acquisition of clinical trial approval, patent rights, and related technical data for a Class 1 Traditional Chinese Medicine new drug, "Chaiqin Ning Shen Granules," for a total consideration of RMB 22 million [1]

Core Viewpoint - The company has signed a technology transfer agreement with Shanxi Traditional Chinese Medicine Research Institute for the new traditional Chinese medicine project, which is expected to enhance its R&D capabilities and competitiveness in the market [1] Group 1: Agreement Details - The company will acquire the clinical trial approval, patent rights, and related technical materials for the traditional Chinese medicine "Chaiqin Ning Shen Granules" for RMB 22 million [1] - This acquisition is categorized as a Class 1 new drug under traditional Chinese medicine [1] Group 2: Strategic Implications - The transfer of technology is expected to accelerate the company's R&D progress for new products and expand its pipeline of innovative traditional Chinese medicines [1] - The agreement aligns with the company's development strategy and is in the interest of all shareholders [1] Group 3: Impact on Financial Performance - The company indicates that due to the lengthy process of advancing various matters, there will be no significant impact on its operating performance in the short term [1]

Group 1 - The company has approved a share repurchase plan at the 2024 annual general meeting, with a total repurchase fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 6.95 per share [1] - The repurchase period is set for a maximum of 6 months from the date of approval, with funds sourced from the company's own and raised funds [1] - As of July 31, 2025, the company has repurchased a total of 200,000 shares, accounting for 0.03% of the total share capital, with a total payment of RMB 1,260,000 at a maximum and minimum transaction price of RMB 6.30 per share [1] Group 2 - The company will adhere to relevant regulations during the repurchase period and will make repurchase decisions based on market conditions, ensuring timely information disclosure [2]

Group 1 - The core point of the article is that Yabao Pharmaceutical announced a share buyback program, having repurchased a total of 200,000 shares as of July 31, 2025, which represents 0.03% of the company's total share capital [2] Group 2 - The share repurchase was conducted through centralized bidding transactions [2] - The announcement was made on the evening of August 1 [2] - The buyback program is part of the company's strategy to enhance shareholder value [2]

亚宝药业集团股份有限公司 证券代码：600351 证券简称：亚宝药业 公告编号：2025-028 亚宝药业集团股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日召开 了 2024 年年度股东大会，审议通过了《关于以集中竞价交易方式回购股份方案的 议案》，同意公司以集中竞价方式回购公司股份，回购股份的资金总额不低于人民 币 0.5 亿元（含）且不超过人民币 1 亿元（含），回购股份价格不超过人民币 6.95 元/股，回购用途为全部予以注销并减少公司注册资本，回购期限为自股东大会审 议通过回购方案之日起不超过 6 个月，本次回购资金来源为公司自有资金及自筹 资 金 。 具 体 内 容 详 见 公 司 于 2025 年 5 月 17 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）及《中国证券报》《上海证券报》上发布的《亚宝药业集团股 份有限公司关于以集中竞价交易方式回购股份的回购报告书》（公告编号： 2025-020）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间应当在每个月 ...

Group 1 - The company, Yabao Pharmaceutical (600351.SH), announced that as of July 31, 2025, it has repurchased a total of 200,000 shares through centralized bidding, accounting for 0.03% of the company's total share capital [1] - The highest and lowest transaction price for the repurchased shares was 6.30 RMB per share, indicating a stable price point during the buyback [1] - The total amount paid for the share repurchase was 1.26 million RMB, excluding transaction fees, reflecting the company's commitment to returning value to shareholders [1]

(责任编辑：宋政 HN002) 格隆汇8月1日｜A股市场中药股逆势上涨，其中，生物谷涨近25%，维康药业20CM涨停，新光药业 (300519)涨13%，大唐药业涨近11%，天目药业(600671)、新天药业(002873)、太龙药业(600222)、奇正 藏药(002287)、贵州百灵(002424)10CM涨停，众生药业(002317)涨超8%，亚宝药业(600351)、沃华医药 (002107)涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅%。 | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76亿 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10. ...

MACD金叉信号形成，这些股涨势不错！ 格隆汇8月1日｜A股市场中药股逆势上涨，其中，生物谷（维权）涨近25%，维康药业（维权）20CM 涨停，新光药业涨13%，大唐药业涨近11%，天目药业、新天药业、太龙药业、奇正藏药、贵州百灵 （维权）10CM涨停，众生药业涨超8%，亚宝药业、沃华医药（维权）涨超6%。 | 代码 | 名称 | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | | 833266 | 生物谷 | 24.91 | 17.60亿 | 51.12 | | 300878 | 维康药业 | 20.00 | 37.10亿 | 71.51 | | 300519 | 新光药业 | 13.04 | 31.76 乙 | 52.71 | | 836433 | 大唐药业 | 10.76 | 22.14亿 | 42.65 | | 600671 | 天目药业 | 10.03 | 18.71亿 | 74.94 | | 002873 | 新天药业 | 10.03 | 29.19亿 | 27.68 | | 600222 | 太龙药业 | 10.00 | 39.14 ...